The Merit WRAPSODY™ Endovascular Stent Graft
Primary Purpose
Venous Stenosis, Venous Occlusion
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
WRAPSODY Stent Graft Placement
Sponsored by
About this trial
This is an interventional treatment trial for Venous Stenosis focused on measuring Dialysis, Venous Stenosis, Venous Occlusion, Stent Graft
Eligibility Criteria
Inclusion Criteria:
- Subject has signed informed consent
- Subject is ≥ 21 years of age
- Subject is undergoing chronic hemodialysis or other forms of renal replacement therapy including transplantation and has one of the following being used: a. AV graft placed in the arm ≥30 days prior OR b. Mature fistula in the arm with at least one successful dialysis session completed
- Angiographic evidence of stenosis
- The target lesion has ≥ 50% stenosis
- Subject has clinical or hemodynamic evidence of a venous outflow stenosis or obstruction
- Full expansion of an appropriately sized standard angioplasty balloon has been achieved during primary angioplasty at the target lesion prior to enrollment
Exclusion Criteria:
- Subject has undergone an intervention (surgical or percutaneous) of the AVF/AVG <30 days from the date of the initial study procedure
- Subject has had a previous stent or stent graft placed in the venous outflow circuit ≤30 days from the date of the initial study procedure
- Active hemodialysis access is not in the arm
- A pseudoaneurysm is present within the target lesion
- Target lesion is in SVC, IJV, under the clavicle, across the elbow, in the needling segment of AVF or AVG anastomosis, located within a stent
- Lesions, other than the target lesion, in the venous outflow circuit with >30% stenosis
- Known or suspected infection of the hemodialysis access site and/or septicemia
- Permanent pacemaker or automated implantable cardioverter defibrillator (AICD) on the side with the target lesion
- Current central venous catheter for dialysis access
- Uncorrectable coagulation disorders
- Hypersensitivity to nickel titanium alloy
- The subject is enrolled in another investigational study
- The subject is unable or unwilling to comply with the protocol requirements
- Life expectancy is ≤ 12 months
- Subject cannot receive heparin or equivalent anticoagulant
- Allergy to radiographic contrast material which cannot be adequately premedicated
- Subject is pregnant, breastfeeding, or pre-menopausal and intending to become pregnant
- Subject's access is anticipated to be abandoned within 3 months
- Subject has a thoracic central vein obstruction that would lead to stent graft placement across the internal jugular vein
- Subject's hemodialysis access is thrombosed
- Active malignancy other than non-melanomatous skin cancer
- Any other condition deemed exclusionary in the opinion of the investigator
Sites / Locations
- G. Gennimatas General Hospital of Athens
- Queen Elizabeth University Hospital
- Oxford University Hospitals NHS Foundation Trust
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
WRAPSODY Stent Graft
Arm Description
All subjects will receive treatment via WRAPSODY Stent Graft Placement.
Outcomes
Primary Outcome Measures
Number of Participants Without Any Localized or Systemic Safety Events Through 30 Days
The total number of subjects without any localized or systemic safety events through 30 days that affect the access or venous outflow circuit and resulted in surgery, hospitalization, or death
Number of Participants With Target Lesion Primary Patency at 30 Days
The total number of subjects with Target Lesion Primary Patency at 30 days
Secondary Outcome Measures
Number of Participants With Target Lesion Primary Patency at 3 Months
The total number of subjects with Target Lesion Primary Patency at 3 months
Number of Participants With Target Lesion Primary Patency at 6 Months
The total number of subjects with Target Lesion Primary Patency at 6 months
Number of Participants With Target Lesion Primary Patency at 12 Months
The total number of subjects with Target Lesion Primary Patency at 12 months
Number of Participants With Assisted Target Lesion Primary Patency at 30 Days
The total number of subjects with Assisted Primary Patency of the Target Lesion at 30 days
Number of Participants With Assisted Target Lesion Primary Patency at 3 Months
The total number of subjects with Assisted Primary Patency of the Target Lesion at 3 months
Number of Participants With Assisted Target Lesion Primary Patency at 6 Months
The total number of subjects with Assisted Primary Patency of the Target Lesion at 6 months
Number of Participants With Assisted Target Lesion Primary Patency at 12 Months
The total number of subjects with Assisted Primary Patency of the Target Lesion at 12 months
Number of Participants With Access Circuit Primary Patency at 30 Days
The total number of subjects with Access Circuit Primary Patency at 30 days
Number of Participants With Access Circuit Primary Patency at 3 Months
The total number of subjects with Access Circuit Primary Patency at 3 months
Number of Participants With Access Circuit Primary Patency at 6 Months
The total number of subjects with Access Circuit Primary Patency at 6 months
Number of Participants With Access Circuit Primary Patency at 12 Months
The total number of subjects with Access Circuit Primary Patency at 12 months
Number of Participants With Assisted Access Circuit Primary Patency at 30 Days
The total number of subjects with Assisted Access Circuit Primary Patency at 30 days
Number of Participants With Assisted Access Circuit Primary Patency at 3 Months
The total number of subjects with Assisted Access Circuit Primary Patency at 3 months
Number of Participants With Assisted Access Circuit Primary Patency at 6 Months
The total number of subjects with Assisted Access Circuit Primary Patency at 6 months
Number of Participants With Assisted Access Circuit Primary Patency at 12 Months
The total number of subjects with Assisted Access Circuit Primary Patency at 12 months
Number of Participants With Clinical Success
The resumption of successful dialysis through existing access for at least one session following the initial study procedure
Number of Participants With Anatomic Success
Less than 30% residual stenosis immediately following the study procedure
Number of Participants With Procedural Success
The achievement of both clinical and anatomic success
Full Information
NCT ID
NCT03644017
First Posted
August 16, 2018
Last Updated
December 22, 2021
Sponsor
Merit Medical Systems, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT03644017
Brief Title
The Merit WRAPSODY™ Endovascular Stent Graft
Official Title
Prospective Investigation of The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Venous Outflow Circuit Obstruction In Hemodialysis Patients
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Completed
Study Start Date
January 29, 2019 (Actual)
Primary Completion Date
February 25, 2020 (Actual)
Study Completion Date
January 20, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merit Medical Systems, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a phase 1 study, designed to evaluate the safety and effectiveness of the WRAPSODY Stent Graft for the treatment of venous outflow circuit obstructions in the veins of the arm or thoracic central veins of subjects who receive chronic dialysis treatment for end stage renal disease.
Detailed Description
The study will consist of a screening period in which subject eligibility will be determined. Approximately 50 subjects meeting the study entry criteria will be enrolled. Placement of the WRAPSODY stent graft will follow the procedure. Post study procedure subjects will have planned follow-up visits at 30 days, 3, 6 and 12months, and additional visits as referred by the subject's dialysis facility.
The primary study safety endpoint will be the proportion of subjects without any localized or systemic safety events through 30 days that affect the access or venous outflow circuit and resulted in surgery, hospitalization, or death. Subjects will continue to be followed up to 12 months for supplementary information.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Stenosis, Venous Occlusion
Keywords
Dialysis, Venous Stenosis, Venous Occlusion, Stent Graft
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single arm treated with investigational device WRAPSODY Stent Graft
Masking
None (Open Label)
Allocation
N/A
Enrollment
46 (Actual)
8. Arms, Groups, and Interventions
Arm Title
WRAPSODY Stent Graft
Arm Type
Experimental
Arm Description
All subjects will receive treatment via WRAPSODY Stent Graft Placement.
Intervention Type
Device
Intervention Name(s)
WRAPSODY Stent Graft Placement
Other Intervention Name(s)
Stent Graft, Covered Stent
Intervention Description
The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
Primary Outcome Measure Information:
Title
Number of Participants Without Any Localized or Systemic Safety Events Through 30 Days
Description
The total number of subjects without any localized or systemic safety events through 30 days that affect the access or venous outflow circuit and resulted in surgery, hospitalization, or death
Time Frame
30 days
Title
Number of Participants With Target Lesion Primary Patency at 30 Days
Description
The total number of subjects with Target Lesion Primary Patency at 30 days
Time Frame
30 days
Secondary Outcome Measure Information:
Title
Number of Participants With Target Lesion Primary Patency at 3 Months
Description
The total number of subjects with Target Lesion Primary Patency at 3 months
Time Frame
3 months
Title
Number of Participants With Target Lesion Primary Patency at 6 Months
Description
The total number of subjects with Target Lesion Primary Patency at 6 months
Time Frame
6 months
Title
Number of Participants With Target Lesion Primary Patency at 12 Months
Description
The total number of subjects with Target Lesion Primary Patency at 12 months
Time Frame
12 months
Title
Number of Participants With Assisted Target Lesion Primary Patency at 30 Days
Description
The total number of subjects with Assisted Primary Patency of the Target Lesion at 30 days
Time Frame
30 days
Title
Number of Participants With Assisted Target Lesion Primary Patency at 3 Months
Description
The total number of subjects with Assisted Primary Patency of the Target Lesion at 3 months
Time Frame
3 months
Title
Number of Participants With Assisted Target Lesion Primary Patency at 6 Months
Description
The total number of subjects with Assisted Primary Patency of the Target Lesion at 6 months
Time Frame
6 months
Title
Number of Participants With Assisted Target Lesion Primary Patency at 12 Months
Description
The total number of subjects with Assisted Primary Patency of the Target Lesion at 12 months
Time Frame
12 months
Title
Number of Participants With Access Circuit Primary Patency at 30 Days
Description
The total number of subjects with Access Circuit Primary Patency at 30 days
Time Frame
30 days
Title
Number of Participants With Access Circuit Primary Patency at 3 Months
Description
The total number of subjects with Access Circuit Primary Patency at 3 months
Time Frame
3 months
Title
Number of Participants With Access Circuit Primary Patency at 6 Months
Description
The total number of subjects with Access Circuit Primary Patency at 6 months
Time Frame
6 months
Title
Number of Participants With Access Circuit Primary Patency at 12 Months
Description
The total number of subjects with Access Circuit Primary Patency at 12 months
Time Frame
12 months
Title
Number of Participants With Assisted Access Circuit Primary Patency at 30 Days
Description
The total number of subjects with Assisted Access Circuit Primary Patency at 30 days
Time Frame
30 days
Title
Number of Participants With Assisted Access Circuit Primary Patency at 3 Months
Description
The total number of subjects with Assisted Access Circuit Primary Patency at 3 months
Time Frame
3 months
Title
Number of Participants With Assisted Access Circuit Primary Patency at 6 Months
Description
The total number of subjects with Assisted Access Circuit Primary Patency at 6 months
Time Frame
6 months
Title
Number of Participants With Assisted Access Circuit Primary Patency at 12 Months
Description
The total number of subjects with Assisted Access Circuit Primary Patency at 12 months
Time Frame
12 months
Title
Number of Participants With Clinical Success
Description
The resumption of successful dialysis through existing access for at least one session following the initial study procedure
Time Frame
30 days
Title
Number of Participants With Anatomic Success
Description
Less than 30% residual stenosis immediately following the study procedure
Time Frame
Immediately following the study procedure
Title
Number of Participants With Procedural Success
Description
The achievement of both clinical and anatomic success
Time Frame
30 days
Other Pre-specified Outcome Measures:
Title
Number of Participants With Stent Graft Integrity (Subset of Subjects With Thoracic Central Venous Target Lesions Only)
Description
Total number of participants (subset of subjects with thoracic central venous target lesions only) with freedom from stent graft fracture, defined as clear interruption of a stent strut observed in a minimum of two projections taken during the 12 month visit or after determined by DMC/CEC examination of X-Ray images.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subject has signed informed consent
Subject is ≥ 21 years of age
Subject is undergoing chronic hemodialysis or other forms of renal replacement therapy including transplantation and has one of the following being used: a. AV graft placed in the arm ≥30 days prior OR b. Mature fistula in the arm with at least one successful dialysis session completed
Angiographic evidence of stenosis
The target lesion has ≥ 50% stenosis
Subject has clinical or hemodynamic evidence of a venous outflow stenosis or obstruction
Full expansion of an appropriately sized standard angioplasty balloon has been achieved during primary angioplasty at the target lesion prior to enrollment
Exclusion Criteria:
Subject has undergone an intervention (surgical or percutaneous) of the AVF/AVG <30 days from the date of the initial study procedure
Subject has had a previous stent or stent graft placed in the venous outflow circuit ≤30 days from the date of the initial study procedure
Active hemodialysis access is not in the arm
A pseudoaneurysm is present within the target lesion
Target lesion is in SVC, IJV, under the clavicle, across the elbow, in the needling segment of AVF or AVG anastomosis, located within a stent
Lesions, other than the target lesion, in the venous outflow circuit with >30% stenosis
Known or suspected infection of the hemodialysis access site and/or septicemia
Permanent pacemaker or automated implantable cardioverter defibrillator (AICD) on the side with the target lesion
Current central venous catheter for dialysis access
Uncorrectable coagulation disorders
Hypersensitivity to nickel titanium alloy
The subject is enrolled in another investigational study
The subject is unable or unwilling to comply with the protocol requirements
Life expectancy is ≤ 12 months
Subject cannot receive heparin or equivalent anticoagulant
Allergy to radiographic contrast material which cannot be adequately premedicated
Subject is pregnant, breastfeeding, or pre-menopausal and intending to become pregnant
Subject's access is anticipated to be abandoned within 3 months
Subject has a thoracic central vein obstruction that would lead to stent graft placement across the internal jugular vein
Subject's hemodialysis access is thrombosed
Active malignancy other than non-melanomatous skin cancer
Any other condition deemed exclusionary in the opinion of the investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James A Gilbert, MD
Organizational Affiliation
Oxford University Hospitals NHS Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
G. Gennimatas General Hospital of Athens
City
Athens
ZIP/Postal Code
115 27
Country
Greece
Facility Name
Queen Elizabeth University Hospital
City
Glasgow
ZIP/Postal Code
G51 4TF
Country
United Kingdom
Facility Name
Oxford University Hospitals NHS Foundation Trust
City
Oxford
ZIP/Postal Code
OX3 7LE
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Merit WRAPSODY™ Endovascular Stent Graft
We'll reach out to this number within 24 hrs